

## Still positive but lowering expectation

Supermax's (SUCB) reported a FY19 core PATAMI of RM119.3m (+12% yoy) that fell short of both the consensus and our forecast, delivering only 90% and 88% of the respective forecasts. The miss was due to weak 4QFY19 results, in which core PATAMI contracted by 56% qoq to RM15.1m. The margin compression during 4QFY19 was due to a sharp spike in raw material costs. As such, we lowered our EPS forecasts for FY20-21 by 10% and cut our 12-month TP to RM1.90, but maintain our BUY call.

### Growth strategy remains unchanged

Despite the hiccups in 4QFY19, management commented that it is continuing with the capacity expansion, as Plant #12 is in the midst of completion and expected to start contributing by year-end. The recently acquired land in Meru, Klang would be used to build 3 plants (#13, #14, #15) which management hopes will grow SUCB's capacity by 60% to 44bn/pcs over the next 5 years. However, we have taken a more conservative approach, as we are forecasting a net incremental capacity at a 7-9% CAGR for the next 3 years. We believe some of the new lines will be used to replace older and less efficient production lines.

### Similar problem across the industry

Management mentioned that the margin contraction during the quarter was due to the increase in raw material costs, as latex prices were up by 23% qoq in 4QFY19. We believe that some of the main challenges limiting the glove makers' ability to raise their selling price are the value perception of latex gloves and nitrile gloves, overcapacity in the latex glove space and the time lag in price setting. We believe that other glove makers with high exposure in the latex glove segment are facing similar problems. We expect the ASP of latex glove to be revised up gradually in the coming months to compensate for the higher cost.

### Maintain BUY with a lower TP of RM1.90

We lower our FY20E-21E EPS by 10% to factor in lower margins, and cut our TP to RM1.90 based on a lower PER target of 18x (previous: 21x) as we now see milder growth, on the CY20E EPS (rolled forward from FY20E). Nonetheless, we keep our BUY rating on the 28% upside potential and 12% yoy earnings growth for FY2020E. Downside risks: i) sharp spike in the volatility of the RM/US\$; and ii) higher-than-expected production costs.

### Earnings & Valuation Summary

FYE 30 June	2018	2019	2020E	2021E	2022E
Revenue (RMm)	1,304.5	1,489.3	1,618.3	1,706.0	2,030.4
EBITDA (RMm)	210.6	230.6	234.4	253.8	272.9
Pretax profit (RMm)	161.9	172.6	194.5	213.9	233.3
Net profit (RMm)	106.7	123.8	139.0	153.0	168.5
EPS (sen)	7.8	9.1	10.2	11.2	12.4
PER (x)	19.0	16.4	14.6	13.2	12.0
Core net profit (RMm)	106.7	123.8	139.0	153.0	168.5
Core EPS (sen)	7.8	9.1	10.2	11.2	12.4
Core EPS growth (%)	58.7	16.0	12.3	10.1	10.1
Core PER (x)	19.0	16.4	14.6	13.2	12.0
Net DPS (sen)	3.9	4.5	4.6	5.1	5.6
Dividend Yield (%)	2.6	3.0	3.1	3.4	3.7
EV/EBITDA (x)	11.0	9.7	10.6	9.8	9.3
Chg in EPS (%)			-10	-10	New
Affin/Consensus (x)			0.9	0.9	-

Source: Company, Bloomberg, Affin Hwang forecasts

Outthink. Outperform.

## Results Note

# Supermax

SUCB MK  
Sector: Rubber Product


RM1.49 @ 30 Aug 2019

**BUY (maintain)**

Upside: 28%

**Price Target: RM1.90**

Previous Target: RM2.30



## Price Performance

	1M	3M	12M
Absolute	-9.1%	-9.1%	-11.3%
Rel to KLCI	-7.4%	-7.8%	0.1%

## Stock Data

Issued shares (m)	1,306.3
Mkt cap	1946.4/462.2
Avg daily vol - 6mth (m)	4.3
52-wk range (RM)	1.3-2.05
Est free float	60.0%
BV per share (RM)	0.83
P/BV (x)	1.79
Net cash/(debt) (RMm)	(263.36)
ROE (2020E)	11.5%
Derivatives	No
Shariah Compliant	Yes

## Key Shareholders

Thai Kim Sin	21.3%
Tan Bee Geok	15.8%

Source: Affin Hwang, Bloomberg

Ng Chi Hoong  
(603) 2146 7470  
chihoong.ng@affinhwang.com

Fig 1: Results Comparison

FYE 30 June (RMm)	4Q FY18	3Q FY19	4Q FY19	Qoq % chg	Yoy % chg	12M FY18	12M FY19	Yoy % chg	Comments
Revenue	329.5	361.2	376.0	4.1	14.1	1,304.5	1,489.3	14.2	The qoq increase in 4Q19 was partly due to the strengthening of the USD against the MYR. The significant increase in cost in 4Q19 was due to the sharp appreciation in latex cost
Op costs	(299.2)	(298.6)	(344.0)	15.2	15.0	(1,134.6)	(1,265.3)	11.5	
EBITDA	30.3	62.6	32.0	(49.0)	5.6	210.6	224.1	6.4	
<i>EBITDA margin (%)</i>	<i>9.2</i>	<i>17.3</i>	<i>8.5</i>	<i>(8.8ppt)</i>	<i>(0.7ppt)</i>	<i>16.1</i>	<i>15.0</i>	<i>(1.1ppt)</i>	
Depn and amort	(10.4)	(10.4)	(11.6)	12.2	11.8	(40.8)	(43.6)	7.0	
EBIT	19.9	52.3	20.4	(61.1)	2.3	169.9	180.4	6.2	
<i>EBIT margin (%)</i>	<i>6.0</i>	<i>14.5</i>	<i>5.4</i>	<i>(9.1ppt)</i>	<i>(0.6ppt)</i>	<i>13.0</i>	<i>12.1</i>	<i>(0.9ppt)</i>	
Int expense	(4.0)	(4.5)	(5.9)	30.2	47.1	(14.0)	(19.7)	41.0	
JV & Associates	2.3	1.7	1.8	4.9	(22.6)	6.0	5.4	(9.9)	
EI	-	-	-	n.m	n.m	-	6.5	n.m	
<b>Pretax profit</b>	<b>18.2</b>	<b>49.4</b>	<b>16.2</b>	(67.2)	(10.8)	<b>161.9</b>	<b>172.6</b>	6.6	
Tax	(7.5)	(14.5)	(2.2)	(84.8)	(70.7)	(51.8)	(49.0)	(5.4)	Normalisation of tax rate in 4QFY19 has helped offset some of the decline in PBT
<i>Tax rate (%)</i>	<i>41.3</i>	<i>29.2</i>	<i>13.5</i>	<i>(15.7ppt)</i>	<i>(27.7ppt)</i>	<i>33.5</i>	<i>30.2</i>	<i>(3.3ppt)</i>	
MI	(1.2)	(0.3)	1.1	(404.9)	(189.2)	(3.5)	0.1	(102.8)	
<b>Net profit</b>	<b>9.5</b>	<b>34.6</b>	<b>15.1</b>	(56.5)	59.0	<b>106.7</b>	<b>123.8</b>	16.0	
EPS (sen)	0.7	2.6	1.1	(56.5)	59.0	8.1	9.4	16.0	
<b>Core net profit</b>	<b>9.5</b>	<b>34.6</b>	<b>15.1</b>	(56.5)	59.0	<b>106.7</b>	<b>119.3</b>	11.9	Below our and consensus estimates

Source: Affin Hwang, Company

## Important Disclosures and Disclaimer

Outthink. Outperform.

### Equity Rating Structure and Definitions

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable and is not to be taken in substitution for the exercise of your judgment. You should obtain independent financial, legal, tax or such other professional advice, when making your independent appraisal, assessment, review and evaluation of the company/entity covered in this report, and the extent of the risk involved in doing so, before investing or participating in any of the securities or investment strategies or transactions discussed in this report. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (expressed or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, estimates, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel and the same are subject to change without notice. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest. Under no circumstances shall the Company, be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company its directors, its employees and their respective associates may have positions or financial interest in the securities mentioned therein. The Company, its directors, its employees and their respective associates may further act as market maker, may have assumed an underwriting commitment, deal with such securities, may also perform or seek to perform investment banking services, advisory and other services relating to the subject company/entity, and may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report. The Company, its directors, its employees and their respective associates, may provide, or have provided in the past 12 months investment banking, corporate finance or other services and may receive, or may have received compensation for the services provided from the subject company/entity covered in this report. No part of the research analyst's compensation or benefit was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Employees of the Company may serve as a board member of the subject company/entity covered in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

This report, or any portion thereof may not be reprinted, sold or redistributed without the written consent of the Company.

This report is printed and published by:  
 Affin Hwang Investment Bank Berhad (14389-U)  
 A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
 69, Jalan Raja Chulan,  
 50200 Kuala Lumpur, Malaysia.

T : + 603 2142 3700  
 F : + 603 2146 7630  
 research@affinhwang.com

www.affinhwang.com